Exon 3 β-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome

被引:87
作者
Johnson, V
Volikos, E
Halford, SE
Sadat, ETE
Popat, S
Talbot, I
Truninger, K
Martin, J
Jass, J
Houlston, R
Atkin, W
Tomlinson, IPM
Silver, ARJ [1 ]
机构
[1] St Marks Hosp, Canc Res UK, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England
[2] St Marks Hosp, Acad Dept Pathol, Harrow, Middx, England
[3] Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England
[4] Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England
[5] Catonal Hosp Aarau, Div Gastroenterol, Aarau, Switzerland
[6] Dept Pathol, Montreal, PQ, Canada
关键词
D O I
10.1136/gut.2004.048132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aim: Activating beta-catenin mutations in exon 3 have been implicated in colorectal tumorigenesis. Although reports to the contrary exist, it has been suggested that beta-catenin mutations occur more often in microsatellite unstable (MSI+) colorectal carcinomas, including hereditary non-polyposis colorectal cancer (HNPCC), as a consequence of defective DNA mismatch repair. We have analysed 337 colorectal carcinomas and adenomas, from both sporadic cases and HNPCC families, to provide an accurate assessment of beta-catenin mutation frequency in each tumour type. Methods: Direct sequencing of exon 3 of beta-catenin. Results: Mutations were rare in sporadic (1/83, 1.2%) and HNPCC adenomas (1/37, 2.7%). Most of the sporadic adenomas analysed (80%) were small (<1 cm), and our data therefore differ from a previous report of a much higher mutation frequency in small adenomas. No oncogenic beta-catenin mutations were identified in 34 MSI+ and 78 microsatellite stable (MSI-) sporadic colorectal cancers but a raised mutation frequency (8/44, 18.2%) was found in HNPCC cancers; this frequency was significantly higher than that in HNPCC adenomas ( p = 0.035) and in both MSI- ( p< 0.0001) and MSI+ ( p = 0.008) sporadic cancers. Mutations were more common in higher stage ( Dukes' stages C and D) cancers ( p = 0.001). Conclusion: Exon 3 beta-catenin mutations are associated specifically with malignant colorectal tumours in HNPCC; mutations appear not to result directly from deficient mismatch repair. Our data provide evidence that the genetic pathways of sporadic MSI+ and HNPCC cancers may be divergent, and indicate that mutations in the HNPCC pathway of colorectal tumorigenesis may be determined by selection, not simply by hypermutation.
引用
收藏
页码:264 / 267
页数:4
相关论文
共 30 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   β-Catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary non-polyposis colorectal cancer patients [J].
Akiyama, Y ;
Nagasaki, H ;
Yagi, KO ;
Nomizu, T ;
Yuasa, Y .
CANCER LETTERS, 2000, 157 (02) :185-191
[3]   Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial [J].
Atkin, WS ;
Cook, CF ;
Cuzick, J ;
Edwards, R ;
Northover, JMA ;
Wardle, J .
LANCET, 2002, 359 (9314) :1291-1300
[4]  
D'Orazio D, 2002, ANTICANCER RES, V22, P3409
[5]  
Hoang JM, 1997, CANCER RES, V57, P300
[6]   DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer [J].
Iino, H ;
Simms, L ;
Young, J ;
Arnold, J ;
Winship, IM ;
Webb, SI ;
Furlong, KL ;
Leggett, B ;
Jass, JR .
GUT, 2000, 47 (01) :37-42
[7]   Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin [J].
Ikeda, S ;
Kishida, S ;
Yamamoto, H ;
Murai, H ;
Koyama, S ;
Kikuchi, A .
EMBO JOURNAL, 1998, 17 (05) :1371-1384
[8]   beta-Catenin mutations in cell lines established from human colorectal cancers [J].
Ilyas, M ;
Tomlinson, IPM ;
Rowan, A ;
Pignatelli, M ;
Bodmer, WF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10330-10334
[9]  
Iwao K, 1998, CANCER RES, V58, P1021
[10]  
Kim IJ, 2003, CLIN CANCER RES, V9, P2920